ASCO Oncology conference: Aeterna Zentaris (AEZS -7.3%) slides after it presented disappointing Phase 3 results for perifosine - one of its lead drug candidates - yesterday. Data from the tests showed no benefit in overall survival when adding perifosine to capecitabine in refractory colorectal cancer.
ASCO Oncology conference: Aeterna Zentaris (AEZS -7.3%) slides after it presented disappointing...
From other sites
at CNBC.com (Nov 6, 2014)
at CNBC.com (Jan 9, 2013)
at CNBC.com (Mar 6, 2012)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs